Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Estrogen Receptor Positive
Open-data reference.
12 US clinical trials · 2 currently recruiting
Active & Recent Trials
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
SWOG Cancer Research Network
NCT03723928
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
Northwestern University
NCT03213041
Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer
University of Nebraska
NCT01750073
Radiation Therapy Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer
M.D. Anderson Cancer Center
NCT03359954
Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy
University of Washington
NCT04692103
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
NCT00785291
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery
Rutgers, The State University of New Jersey
NCT02526498
Safety, Feasibility and Efficacy of Vitamin D Supplementation in Women With Metastatic Breast Cancer (SAFE-D)
Loyola University
NCT02186015
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
M.D. Anderson Cancer Center
NCT02152943
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
Northwestern University
NCT02536794
FLT PET in Measuring Treatment Response in Patients With Newly Diagnosed Estrogen Receptor-Positive, HER2-Negative Stage I-III Breast Cancer
University of Washington
NCT01928186
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
NCT01281150
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Estrogen Receptor Positive Trial Landscape
ClinicalTrials.gov lists 12 US studies indexed under Estrogen Receptor Positive, and 2 of those are currently open to recruitment — roughly 17% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Estrogen Receptor Positive shows 1 late-stage studies (Phase 3 and Phase 4 combined) alongside 9 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Estrogen Receptor Positive is led by Northwestern University with 2 indexed trials, alongside 7 other organizations in the top contributor list. The list on this page surfaces up to 12 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Estrogen Receptor Positive?
PlainTrial tracks 12 US clinical trials for Estrogen Receptor Positive, of which 2 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Estrogen Receptor Positive?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.